Ambarish Athavale, MD
Nephrology · San Diego, CANPI 1255647145
Payments from drug & device makers
Across 146 payments — averaging $857.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$82K
- Calliditas Therapeutics US Inc.$16K
- Aurinia Pharma U.S., Inc.$6K
- Travere Therapeutics, Inc.$6K
- Vertex$5K
- Idorsia Pharmaceuticals US Inc$4K
- plus $6K from 12 others
What the payments were for
- Consulting fees$58,43670%
- Speaking & faculty fees$15,20018%
- Travel & lodging$3,9625%
- Food & beverage$5,1556%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 19 | $81,574 |
| Calliditas Therapeutics US Inc. | 22 | $15,792 |
| Aurinia Pharma U.S., Inc. | 6 | $6,250 |
| Travere Therapeutics, Inc. | 40 | $6,056 |
| Vertex | 6 | $5,175 |
| Idorsia Pharmaceuticals US Inc | 3 | $4,110 |
| Novartis | 5 | $4,025 |
| Otsuka America Pharmaceutical, Inc. | 20 | $885 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $385 |
| AstraZeneca(2 entities) | 10 | $224 |
| Amgen | 2 | $135 |
| Nxstage Medical, Inc. | 2 | $134 |
| Outset Medical Inc | 1 | $124 |
| Genentech USA, Inc. | 1 | $120 |
| Mallinckrodt Hospital Products Inc. | 1 | $113 |
| Ardelyx, Inc. | 1 | $67 |
| GSK | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- narsoplimab$39,232
- TARPEYO$15,206
- LUPKYNIS$6,250
- Tryvio$4,060
- Fabhalta$3,851
- Filspari$1,185
- JYNARQUE$241
- Rituxan$120
- NXSTAGE SYSTEM ONE$114
- ACTHAR$113
How this compares
$125,235 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 49 | $77,720 |
| RenvelaSevelamer Carbonate | 15 | $24,469 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $17,166 |
| Sevelamer Carbonate | 33 | $9,517 |
| Bumetanide | 26 | $1,444 |
| Calcitriol | 23 | $566 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $546 |
| Losartan Potassium | 53 | $412 |
| Nifedipine ErNifedipine | 11 | $374 |
| Carvedilol | 15 | $271 |
| Chlorthalidone | 17 | $262 |
| Tamsulosin Hcl | 19 | $245 |
| Furosemide | 36 | $242 |
| Potassium Chloride | 16 | $181 |
| Amlodipine Besylate | 35 | $139 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Diego
- Hui XueSan Diego$1.6M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.